New Triple-Drug cocktail aims to tackle tough breast cancer

NCT ID NCT05422794

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 6 times

Summary

This early-phase trial tests a new drug called ZEN003694 combined with immunotherapy (pembrolizumab) and chemotherapy (nab-paclitaxel) in 57 people with advanced triple-negative breast cancer. The goal is to find a safe dose and see if the combo can shrink tumors or slow the cancer's growth. It's a first step to see if this approach is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZEN003694 (a BET inhibitor) combined with pembrolizumab (immunotherapy) and nab-paclitaxel (chemotherapy)
What this could lead to: If it works, this could lead to a more effective treatment for advanced triple-negative breast cancer, potentially shrinking tumors or slowing their growth.
What could go wrong: This is an early phase 1 trial with only 57 people, so it's mainly checking safety and dosing. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANATOMIC STAGE III BREAST CANCER AJCC V8 ANATOMIC STAGE IV BREAST CANCER AJCC V8 LOCALLY ADVANCED TRIPLE-NEGATIVE BREAST CARCINOMA METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA

Contacts and locations

Show contact details

Locations

Boston Medical Center
RECRUITING

Boston, Massachusetts, 02118, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
RECRUITING

New York, New York, 10016, United States

Contact Email: •••••@•••••
NYU Langone Hospital - Long Island
RECRUITING

Mineola, New York, 11501, United States

Contact Email: •••••@•••••
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
Vanderbilt Breast Center at One Hundred Oaks
RECRUITING

Nashville, Tennessee, 37204, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.